Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
PARP inhibitor
Biotech
Roche pays Repare $125M to join Big Pharma peers in cancer race
Roche is joining AstraZeneca, Bayer, Merck KGaA and more in a synthetic lethality race, paying $125 million upfront for an ATR inhibitor.
Nick Paul Taylor
Jun 2, 2022 8:27am
AstraZeneca re-ups ties with Chinese cancer test maker AmoyDx
Apr 18, 2022 10:42am
Ribon raises $65M to take PARP7 inhibitor deeper into the clinic
Jul 14, 2021 8:20am
Combating BRCA-mutated tumors via a new pathway
Jun 17, 2021 11:00am
Valo to go public via Khosla-backed SPAC, gaining $500M-plus
Jun 10, 2021 4:11am
AACR: Zentalis' WEE1 inhibitor shows promise in phase 1
Apr 10, 2021 1:30pm